The FDA Oncologic Drugs Advisory Committee May 14 voted 8-3 against approval of quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia which is FLT3- ITD positive, as detected by an FDA-approved test.
The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.
